Parameter
| Biomarker | qPET | Full name | Quantitative positron emission tomography (SUVmax/SUVpeak ratio) | Molecular Type | Imaging-molecular composite index (SUV ratio) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Treatment response prediction, risk stratification |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | PET/CT imaging (SUVpeak/SUVmean calculation) | ||
| Pathobiological Mechanisms | Quantify tumor metabolic activity to differentiate high-risk (qPET>3, EFS=47.6%) and low-risk (qPET≤3, EFS>83%) patients with vDS5. | ||||
| Clinical Availability Status | Clinical translation phase: Expansion of vDS ordinal classification to provide a basis for individualized treatment strategies for vDS5 patients. | ||||
| Notes and Dynamics | Patients with qPET<1.3 may skip radiotherapy, while those with qPET>3 require treatment regimen adjustment, as validated in pediatric cHL. | ||||